Iovance Biotherapeutics I... (IOVA)
The price, the headline numbers and the latest news, in one place.
Iovance Biotherapeutics Inc. (IOVA) Stock Price, Analysis & Data
| Bid | 3.76 |
| Market Cap | 3.65B |
| Revenue (ttm) | 324.97M |
| Net Income (ttm) | -289.52M |
| 0.70 | |
| -0.67 | |
| n/a | |
| -30.32 | |
| P/B (ttm) | 4.96 |
| P/S (ttm) | 11.23 |
| Earnings Date | Nov 5, 2026 |
| Ask | 4.98 |
| Volume | 15,717,237 |
| Avg. Volume (20D) | 16,847,358 |
| Open | 8.07 |
| Previous Close | 8.29 |
| Day's Range | 7.79 - 8.36 |
| 52-Week Range | 1.76 - 9.36 |
| Analyst | Buy |
| Price Target | 9 (11.66%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresecta...
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was 263.5M, an increase of 60.6% compared to the previous year's 164.07M. Earnings were -390.98M, an increase of 5.05%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for IOVA stock is "Buy". The 12-month stock price forecast is 9, which is upside of 11.66% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $99.31M misses estimates by $0, with 65.65% YoY growth.
- EPS of -0.11 exceeds estimates by 0.02, with 66.67% YoY growth.
Analysts project revenue of ... Upgrade
